ENDOLOGIX
Endologix develops and manufactures minimally invasive treatments for aortic disorders. Endologix's flagship product is the Powerlink(R) System, which is an endovascular stent graft for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 75%, making it a leading cause of death in the U.S.
ENDOLOGIX
Industry:
Biotechnology Health Care Therapeutics
Founded:
1992-01-01
Address:
Irvine, California, United States
Country:
United States
Website Url:
http://www.endologix.com
Total Employee:
501+
Status:
Active
Contact:
(949) 595-7327
Email Addresses:
[email protected]
Total Funding:
210.6 M USD
Technology used in webpage:
SPF Domain Not Resolving Mobile Non Scaleable Content Microsoft Exchange Online Office 365 Mail IPv6 Microsoft Azure DNS Google Google Cloud ASP.NET
Similar Organizations
Adamas Pharmaceuticals
Adamas Pharmaceuticals develops controlled release combination therapeutics for infectious diseases and central nervous system disorders.
Akebia Therapeutics
Akebia Therapeutics develops treatments for ischemia and vascular diseases.
BioVectra
BioVectra offers contract development and manufacturing capacity for intermediates and active pharmaceutical ingredients.
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Milestone Pharmaceuticals
Milestone Pharmaceuticals is a drug development company developing small molecule therapeutics for the treatment of cardiovascular diseases.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2021-04-13 | PQ Bypass | PQ Bypass acquired by Endologix | N/A |
| 2015-10-26 | TriVascular | TriVascular acquired by Endologix | 211 M USD |
| 2010-10-28 | Nellix | Nellix acquired by Endologix | N/A |
Investors List
Greenspring Associates
Greenspring Associates investment in Post-IPO Debt - Endologix
Deerfield
Deerfield investment in Post-IPO Debt - Endologix
Essex Woodlands Healthcare Partners
Essex Woodlands Healthcare Partners investment in Post-IPO Equity - Endologix
Key Employee Changes
| Date | New article |
|---|---|
| 2021-11-10 | Endologix Names Dr. Matthew Thompson President and CEO |
| 2020-04-14 | Endologix Appoints Tim A. Benner as Chief Commercial Officer |
Official Site Inspections
http://www.endologix.com Semrush global rank: 1.98 M Semrush visits lastest month: 10.79 K
- Host name: 141.193.213.11
- IP address: 141.193.213.11
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
